Male Hypogonadism Global Market Report 2024

The male hypogonadism market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to factors such as an aging population, increased awareness and diagnosis, lifestyle factors, the prevalence of chronic illnesses, and the patterns of treatment-seeking behavior.

The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $4.77 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The increase projected for the upcoming period can be ascribed to the heightened awareness, the prevalence of lifestyle-related conditions, advancements in therapies, a focus on men's health, and improved accessibility to telemedicine and healthcare. Notable trends expected in the forecast period encompass a heightened emphasis on psychological and sexual health, the exploration of nutraceuticals and lifestyle interventions, the expansion of markets in emerging economies, collaborative research initiatives, and an increased focus on long-term safety and monitoring.

The anticipated rise in infertility rates is poised to drive the expansion of the male hypogonadism market in the future. Infertility, defined as the inability to conceive after 12 months or more of frequent, unprotected sexual activity, affects both male and female reproductive systems. Male hypogonadism, a potential contributor to reduced sperm production and infertility, is expected to witness increased prevalence, further fueling the growth of the male hypogonadism market. Notably, data from the National Institutes of Health (NIH) in North America, as of March 2023, indicates male infertility rates estimated at 4.5% - 6%, 9% in Australia, and possibly ranging from 8% to 12% in Eastern Europe. Additionally, a 2021 study in the Libyan Journal of Medical Sciences attributes around 70% of infertility cases in Libya to male factors, underscoring the role of male hypogonadism in this context.

The escalating incidence of chronic diseases is anticipated to be a driving force behind the male hypogonadism market's growth. Chronic diseases, lasting a year or more and requiring continuous medical attention, significantly impact hormone production pathways, leading to an elevated occurrence of male hypogonadism due to their effects on testosterone synthesis and regulation. For example, projections from the National Center for Biotechnology Information (NCBI) in January 2023 suggest a substantial surge, reaching 142.66 million individuals aged 50 and older with at least one chronic illness by 2050, compared to 71.522 million in 2020. Consequently, the rising prevalence of chronic diseases is expected to contribute to the expansion of the male hypogonadism market.

A prominent trend is the increasing popularity of product innovations. Companies within this sector are actively pursuing the development of novel products to maintain their competitive positions. For example, in June 2022, Halozyme, a biotechnology company based in the United States, introduced Tlando, an oral treatment designed for testosterone replacement therapy in male hypogonadism. Tlando, a prescription drug containing testosterone, represents a milestone as the first FDA-approved oral testosterone treatment. Its application is targeted at adult men experiencing low or no testosterone due to specific medical conditions.

Major players in the male hypogonadism market are strategically directing their efforts toward creating innovative products, including digital-forward platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and simplify access to treatments, thereby revolutionizing the care landscape for male hypogonadism while enhancing patient support and treatment accessibility. An illustrative example is Base Healthcare, a U.S.-based men's virtual health platform, which, in October 2022, launched a subscription-based platform exclusively for men. This digital health platform prioritizes fundamental health and hormone enhancement through oral testosterone treatment, offering users convenient access to adequate testosterone therapy (ATT), certified medical professionals, and personalized health guidance.

In July 2022, Gruenenthal, a pharmaceutical company headquartered in Germany, acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition is strategically aimed at enhancing Gruenenthal’s profitability and enabling increased investment in research and development to pave the way for the next generation of pain therapies. Bayer AG, a renowned German pharmaceutical company, plays a pivotal role in the male hypogonadism treatment sector, further influencing the market landscape.

Major companies operating in the male hypogonadism market report are Allergan plc, Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, AstraZeneca plc, IBSA Institut Biochimique SA, Juniper Laboratories SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Endocrine Technologies Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Mereo BioPharma Group plc, Myovant Sciences Ltd., Novartis AG, Novo Nordisk A/S, Repros Therapeutics Inc., Sandoz International GmbH, Sanofi SA, Sermonix Pharmaceuticals LLC, Shionogi & Co. Ltd., Solvay SA, TherapeuticsMD Inc., Viking Therapeutics Inc.

North America was the largest region in the male hypogonadism market in 2023. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that manifests in boys when they have an extra copy of the X chromosome at birth. Treatment for male hypogonadism often involves testosterone therapy delivered through various methods such as topical gels, injectables, transdermal patches, and gonadotropin-releasing hormone therapy.

The male hypogonadism market research report is one of a series of new reports that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.